Vir Biotechnology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $68.6M | $74.2M | $86.2M | $1.6B | $1.1B |
| Cost of revenue | $26,000 | $845,000 | $2.8M | $146.3M | $65.9M |
| Selling, general & administrative | $92.1M | $119.0M | $174.4M | $161.8M | $160.8M |
| Research and development | $456.0M | $506.5M | $579.7M | $474.6M | $448.0M |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M |
| Pretax income | -$437.8M | -$523.1M | -$628.2M | $754.3M | $549.8M |
| Income tax expense | $217,000 | -$1.1M | -$13.1M | $238.4M | $21.2M |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M |
| Balance Sheet | |||||
| Cash and equivalents | $232.2M | $222.9M | $241.6M | $848.6M | $347.8M |
| Current assets | $514.1M | $1.0B | $1.6B | $2.5B | $1.6B |
| Total assets | $1.0B | $1.4B | $1.9B | $2.8B | $2.0B |
| Current liabilities | $92.8M | $119.7M | $175.4M | $511.0M | $341.2M |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M |
| Stockholders' equity | $765.3M | $1.2B | $1.6B | $2.1B | $1.4B |
| Cash Flow Statement | |||||
| Cash from operations | -$391.8M | -$446.4M | -$778.8M | $1.7B | -$47.6M |
| Depreciation and amortization | $11.7M | $14.6M | $19.5M | $6.8M | $5.3M |
| Stock-based compensation | $49.1M | $78.5M | $111.3M | $102.1M | $83.8M |
| Capital expenditure | $4.8M | $7.3M | $21.6M | $68.0M | $21.8M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.6B | -$69.4M |
| Impairments | $0 | $0 | $7.7M | $0 | $0 |
Shares outstanding 168.7M · Free float 81.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.